Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stanford Chemists Synthesize Compound that Flushes Out Latent HIV

Published: Monday, July 23, 2012
Last Updated: Monday, July 23, 2012
Bookmark and Share
A new collection of compounds, called "bryologs" - derived from a tiny marine organism - activate hidden reservoirs of the virus that currently make the disease nearly impossible to eradicate.

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

Patients must adhere to a demandingly regular drug regimen that carries plenty of side effects. And while the therapy may be difficult to undergo in the United States, it is nearly impossible to scale to the AIDS crisis in the developing world.

The problem with HAART is that it doesn't address HIV's so-called proviral reservoirs - dormant forms of the virus that lurk within T-cells and other cell types.

Even after all of the body's active HIV has been eliminated, a missed dose of antiretroviral drugs can allow the hibernating virus to emerge and ravage its host all over again.

"It's really a two-target problem," said Stanford chemistry Professor Paul Wender, "and no one has successfully targeted the latent virus."

But Wender's lab is getting closer, exciting many HIV patients hoping for a cure.

The lab has created a collection of "bryologs" designed after a naturally occurring, but difficult to obtain, molecule. The new compounds have been shown to activate latent HIV reservoirs with equal or greater potency than the original substance. The lab's work may give doctors a practical way to flush out the dormant virus.

The findings were published on July 15 in the journal Nature Chemistry.

Nature's medicine
The first attempts to reactivate latent HIV were inspired by observations of Samoan healers. When ethnobotanists examined the bark of Samoa's mamala tree, traditionally used by healers to treat hepatitis, they found a compound known as prostratin.

Prostratin binds to and activates protein kinase C, an enzyme that forms part of the signaling pathway that reactivates latent viruses. The discovery sparked interest in the enzyme as a potential therapeutic target, especially as it was discovered that prostratin isn't the only biomolecule to bind to the kinase.

The bryozoan Bugula neritina - a mossy, colonial marine organism - produces a protein kinase C-activating compound that is many times more potent than prostratin. The molecule, named bryostatin 1, was deemed to hold promise as a treatment, not only for HIV but for cancer and Alzheimer's disease as well.

The National Cancer Institute initiated a Phase II clinical trial for the compound in 2009 for the treatment of non-Hodgkin lymphoma. But the substance had a number of side effects and proved prohibitively difficult to produce.

"It took 14 tons of bryozoans to make 18 grams of bryostatin," said Wender. "They've stopped accrual in trials because, even if the trials worked, the compound cannot be currently supplied."

Patient enrollment was suspended until more accessible compounds came out of the Wender Group's lab.

A synthetic approach
Wender, who published the first practical synthesis of prostratin and its analogs in 2008, had set out to make a simpler, more effective synthetic analog of bryostatin.

"We can copy the molecule," he said, "or we can learn how it works and use that knowledge to create something that has never existed in nature and might be superior to it."

The seven resulting compounds, called bryologs, share two fundamental features with the original bryostatin: the recognition domain, which directly contacts protein kinase C, and the spacer domain, which allows the bryolog-protein kinase C complex to be inserted into the cell membrane.

The researchers tested the new compounds' ability to reactivate viral reservoirs in J-Lat cell lines, which contain latent HIV and begin to fluoresce when they express the virus.

In the J-Lat line, bryologs induced virus in as many or more cells than bryostatin at a variety of concentrations, and ranged from 25 to 1,000 times more potent than prostratin. The compounds showed no toxic effects.

Bryolog testing remains in the early stages - the researchers are currently conducting in vivo studies in animal models. But practical bryostatin substitutes may be the first step toward true HIV-eradication therapy.

"I receive letters on a regular basis from people who are aware of our work - who are not, so far as I know, scientifically trained, but do have the disease," said Wender. "The enthusiasm they express is pretty remarkable. That's the thing that keeps me up late and gets me up early."

The research was supported by the National Institutes of Health.

Primary authors are Stanford chemistry graduate student Brian Loy and doctoral students Brian DeChristopher and Adam Schrier, in collaboration with Professor Jerry Zack, co-director of the UCLA AIDS Center, and Dr. Matthew Marsden from the UCLA School of Medicine.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Wednesday, August 24, 2016
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
Friday, August 12, 2016
Mapping Antibody Creation in Humans
Researchers have created the first, detailed map of the body's antibody production, which could suggest new treatment options for immune disorders.
Wednesday, August 03, 2016
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Wednesday, July 06, 2016
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Monday, June 20, 2016
$10M Grant Funds Infection-Focused Center
The new center will explore intracellular and intercellular processes by which salmonella bacteria, responsible for more than 100 million symptomatic infections annually, infect immune cells.
Wednesday, April 06, 2016
Glucose-Guzzling Immune Cells May Drive Coronary Artery Disease
Researchers at Stanford University have found excessive glucose uptake by inflammatory immune cells called macrophages, which reside in arterial plaques, may be behind coronary artery disease.
Wednesday, March 16, 2016
Mapping the Mechanical Properties of Living Cells
Researchers have developed a new way to use atomic force microscopy to rapidly measure the mechanical properties of cells at the nanometer scale, an advance that could pave the way for better understanding immune disorders and cancer.
Monday, December 21, 2015
Viral Infections Leave a Signature on the Immune System
A test that queries the body’s own cells can distinguish a viral infection from a bacterial infection and could help doctors know when to use antibiotics.
Thursday, December 17, 2015
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Friday, July 31, 2015
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Thursday, July 30, 2015
Genetic Signature Enables Early, Accurate Sepsis Diagnosis
Systemic inflammation after injuries or surgery can dramatically alter the activity of thousands of genes, but a new study shows that changes in just 11 of them are enough to detect the presence or absence of accompanying infection.
Monday, May 18, 2015
Foreign Antibodies Mobilize Immune System to Fight Cancer
A mouse’s T cells can be primed to attack and eliminate a malignant tumor by injecting antibodies from another mouse with resistance to the tumor, as well as by activating certain signaling cells, a study has found.
Thursday, May 07, 2015
Stanford Research Leads to New Understanding of How Cells Grow and Shrink
Researchers use new techniques to document how cells can conceal growth and then suddenly swell up.
Saturday, May 17, 2014
Immune Response Triggered by Honeybee Venom Supports Hypothesis on the Origin of Allergies
Allergy-like immune reactions could represent a mechanism of the body that protects it against toxins.
Wednesday, November 27, 2013
Scientific News
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Probe Detects Histone Modifications in Cells
Scientists have developed an antibody probe that can be used to monitor the dynamics of histone modification.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!